Navigation Links
Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements
Date:3/29/2011

MONMOUTH JUNCTION, N.J., March 29, 2011 /PRNewswire/ -- Tris Pharma, Inc., a specialty pharmaceutical company, announced today the highly anticipated re-launch of the MyKidz® Iron product line.  Since the 2007 launch of MyKidz Iron, it has attracted a loyal following of pediatricians, pediatric nurses and mothers.  When the previous marketer decided to focus its product pipeline in a different direction, availability of MyKidz Iron™ became limited, but the need for a great tasting iron supplement remained.  Tris Pharma is stepping-in to provide continuity of care, broader distribution, and ensure that the nutritional needs of infants and toddlers do not go unanswered.

MyKidz Iron products are a line of iron supplements without the strong metallic taste common to other marketed iron supplements.  MyKidz Iron products are based on a patent-pending, taste-neutral formula where the bad-tasting iron is complexed in a polymeric matrix. The formula further contains a berry/banana fruit flavor that makes it a pleasant tasting supplement which helps to increase compliance.  Dr. Louis Reed, a Texas based Pediatrician who has always recommended these supplements, said, "I like MyKidz Iron products because they are the only iron supplements that don't taste like rusty nails, so kids will actually take them."  Additionally, these supplements contain no artificial dyes, alcohol or sugars and the special formula helps to reduce the staining of teeth associated with iron.  

Iron deficiency is a common problem among children, but it is frequently not detected, and it has long-term health implications for children.  It can lead to anemia and/or irreversible effects on children's cognitive and behavioral development.  Studies have shown that 4 percent of 6 month olds and 12 percent of 12 month olds tend to be iron deficient.  Children between the ages of 1-3 years of age have rates of iron deficiency between 6-15 percent.  Pre-term infants, infants who are exclusively breastfed and infants who are at risk for developmental disabilities seem to be at higher risk to develop iron deficiency (1).

"When we received overwhelming feedback," said Ketan Mehta, President and CEO of Tris Pharma, "we realized that there was still a need for a children's iron supplement that was not met by other alternatives.  By making these products available again we, at Tris Pharma, expect the MyKidz Iron product line will positively impact the above statistics."

Three formulations are currently available:

  • MyKidz Iron is an iron supplement with vitamins A, C & D, a 2ml dose delivers 10mg of elemental iron plus 1500 IU of Vitamin A, 35mg of Vitamin C and 400 IU of Vitamin D.
  • MyKidz Iron 10 is a high dose iron only, a 1.5 ml dose delivers 15mg of elemental iron.
  • MyKidz Iron FL is a prescription iron supplement with vitamins A, C & D, plus fluoride.  In addition to the 10mg of elemental iron and above stated vitamin concentrations, it contains .25mg of fluoride per dose for toddlers requiring fluoride supplementation.

Tris Pharma has launched a new website with detailed information about these iron supplements. For more information including full prescribing information, please visit www.mykidziron.com or call toll free (866)697-9283.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of drug delivery technology based products.  Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill.  Tris' research, development, and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, visit www.trispharma.com.

MyKidz is a trademark of Tris Pharma, Inc.

REFERENCE:

1.  AAP News Release "AAP OFFERS GUIDANCE TO BOOST IRON LEVELS IN CHILDREN." Website. http://www.aap.org/pressroom/Ironfinal.pdf.  October 5, 2010.

© 2011 Tris Pharma, Inc.  Monmouth Junction, NJ.


'/>"/>
SOURCE Tris Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... VENICE, Fla. , Feb. 5, 2016 /PRNewswire/ ... Centers , is the first of its kind ... of undesired tattoos through advanced laser treatment. The ... Florida,s Suncoast by storm with ... video consultations, and advanced multi-wavelength Astanza Trinity technology. ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
(Date:2/5/2016)... Site Profile: --> ... The Speech Recognition People, announced their latest primary healthcare case study ... reduce turnaround times and to save the practice money. ... 2013 Challenge: --> ,- Wirral CCG ,- ... Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... the election of Patrick McDermott as Chairman of the National Board of Directors. Mr. ... as Chairman of the Board,” stated Leslie A. Chambers , APDA President and ...
(Date:2/5/2016)... San Francisco, CA (PRWEB) , ... February 05, ... ... dentist and founder of CitiDent, announces that it is now welcoming ... by Dr. Cheng, CitiDent offers a complete range of oral health care, including ...
(Date:2/5/2016)... ... 2016 , ... Health and wellness is a topic that should concern all ... are experiencing an illness. Migraines are a severe form of a headache and often ... not wish the pain on their worst enemy, the feeling can last for many ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):